Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
In development
Reference number: GID-TA10886
Expected publication date: TBC
The company, GlaxoSmithKline, has been in touch with NICE to request a delay to the submission. As a consequence, the appraisal committee discussion originally scheduled for 8 February 2023 has been cancelled.
A new Committee meeting date has been scheduled for 5 April 2023. The deadline for evidence submission is now 5pm on 6 October 2022 and we anticipate that technical engagement will be in mid-January 2023.
Further updates will be available in due course.